Abstract
B cells play an important role in the pathogenesis of rheumatoid arthritis (RA). Rituximab is a chimeric monoclonal antibody that depletes B-cells by binding to the CD20 surface antigen that has been approved for the treatment of RA. Its efficacy has been clearly demonstrated by different clinical trials and, recently, in long-term observational studies. The use of rituximab in clinical practice has highlighted its efficacy and safety over more than 5 years of treatment, as well as to try to understand the timing for retreatment of patients relapsing after a good initial response.
| Original language | English |
|---|---|
| Pages (from-to) | 591-594 |
| Number of pages | 4 |
| Journal | Autoimmunity Reviews |
| Volume | 8 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - Jun 2009 |
Fingerprint
Keywords
- B-lymphocyte
- Rheumatoid arthritis
- Rituximab
ASJC Scopus subject areas
- Immunology
- Immunology and Allergy
Cite this
Long term treatment of rheumatoid arthritis with rituximab. / Caporali, Roberto; Caprioli, Marta; Bobbio-Pallavicini, Francesca; Bugatti, Serena; Montecucco, Carlomaurizio.
In: Autoimmunity Reviews, Vol. 8, No. 7, 06.2009, p. 591-594.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Long term treatment of rheumatoid arthritis with rituximab
AU - Caporali, Roberto
AU - Caprioli, Marta
AU - Bobbio-Pallavicini, Francesca
AU - Bugatti, Serena
AU - Montecucco, Carlomaurizio
PY - 2009/6
Y1 - 2009/6
N2 - B cells play an important role in the pathogenesis of rheumatoid arthritis (RA). Rituximab is a chimeric monoclonal antibody that depletes B-cells by binding to the CD20 surface antigen that has been approved for the treatment of RA. Its efficacy has been clearly demonstrated by different clinical trials and, recently, in long-term observational studies. The use of rituximab in clinical practice has highlighted its efficacy and safety over more than 5 years of treatment, as well as to try to understand the timing for retreatment of patients relapsing after a good initial response.
AB - B cells play an important role in the pathogenesis of rheumatoid arthritis (RA). Rituximab is a chimeric monoclonal antibody that depletes B-cells by binding to the CD20 surface antigen that has been approved for the treatment of RA. Its efficacy has been clearly demonstrated by different clinical trials and, recently, in long-term observational studies. The use of rituximab in clinical practice has highlighted its efficacy and safety over more than 5 years of treatment, as well as to try to understand the timing for retreatment of patients relapsing after a good initial response.
KW - B-lymphocyte
KW - Rheumatoid arthritis
KW - Rituximab
UR - http://www.scopus.com/inward/record.url?scp=67349120767&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67349120767&partnerID=8YFLogxK
U2 - 10.1016/j.autrev.2009.02.008
DO - 10.1016/j.autrev.2009.02.008
M3 - Article
C2 - 19393205
AN - SCOPUS:67349120767
VL - 8
SP - 591
EP - 594
JO - Autoimmunity Reviews
JF - Autoimmunity Reviews
SN - 1568-9972
IS - 7
ER -